White House Withdraws Heidi Overton's FDA Nomination as Senate Support Fails to Materialize
With Overton's nomination pulled before a Senate vote, the Trump administration has no confirmed pick to lead the Food and Drug Administration and must find a new candidate who can win enough votes.
By Hushread Stories, from 21 outlets · First published 18 Nov 2026
In brief
- The White House has withdrawn Dr. Heidi Overton's nomination to lead the Food and Drug Administration, as confirmed by a White House official.
- Senator Bill Cassidy publicly criticized the withdrawal, saying Overton probably had the votes needed for confirmation.
- The withdrawal came less than 24 hours before a Senate health committee vote that had been scheduled for Wednesday morning.
- Reports also described an icy relationship between Overton and Health and Human Services Secretary Robert F Kennedy Jr, though the administration has not changed its view of her publicly.
- The FDA still has no nominee for commissioner, and no replacement or timeline has been announced.
Timeline · 6 moments
White House withdraws Heidi Overton's nomination to lead the FDA
NYT > Science ↗AP says White House pulled pick as GOP support faltered
Associated Press ↗Endpoints News reports Overton pulled amid uncertain Senate support
Endpoints News ↗White House official confirms nomination dropped before vote
CNN Top Stories ↗Axios reports White House dropping her nomination
Axios ↗Overton reported struggling to win Republican support
CBS Top Stories ↗Update 18 Nov 2026, 10:47 pm UTC
Senator Bill Cassidy, the chairman of the Senate health committee, publicly criticized the White House for pulling the nomination, saying Overton probably had the votes to be confirmed. Endpoints News reported on how the confirmation effort fell apart in the hours before the scheduled HELP Committee vote. The core facts of the withdrawal are unchanged, but the new coverage adds a sharper dispute over whether the nomination was actually doomed.
Update 18 Nov 2026, 2:06 pm UTC
The new coverage, including AP and The Independent, confirms the White House pulled Dr. Heidi Overton's nomination on Tuesday, and adds that her relationship with Health and Human Services Secretary Robert F Kennedy Jr was reported as strained. The core outcome in the headline is unchanged, so the headline stands and the key points now carry the additional context on Senate opposition.
Update 18 Nov 2026, 7:50 am UTC
The withdrawal is now confirmed by several outlets, with the New York Times and The Washington Post reporting that the White House pulled the nomination before a scheduled Senate health committee vote on Wednesday morning. Coverage also says the reason was a shortage of Republican support, and the published explainer's core claims still hold. Nothing in the new reporting names a replacement nominee, so the open question about who will lead the FDA remains unanswered.
How it started
President Trump had nominated Dr. Heidi Overton to run the Food and Drug Administration, the agency that regulates drugs, medical devices and much of the food supply.
Any FDA commissioner needs Senate confirmation, which means the nominee has to win over enough senators, in practice including Republicans, who hold the majority's say over what moves forward.
How it unfolded
On November 17, CBS reported that Overton was having trouble finding enough Republican support to advance her nomination. The report added that the nomination could be pulled if she fell short.
The same day, Axios reported a scoop that the White House was dropping her nomination because of a lack of congressional support.
On November 18, the White House put it on the record. CNN reported that a White House official confirmed on Tuesday the administration was dropping Overton in the face of Senate opposition, with the decision coming ahead of a confirmation vote.
Endpoints News described the same move, saying she was pulled from consideration according to a White House official, and framed it as a result of uncertain Senate support. The Associated Press said the White House had pulled the nomination amid growing indications she did not have the votes to be confirmed.
The New York Post also obtained confirmation from a White House official and characterized the pushback as bipartisan. That differs somewhat from the framing elsewhere, where the emphasis falls mainly on faltering Republican support.
Where it stands
Overton's nomination is withdrawn, so she will not face the Senate vote that had been on the calendar. The coverage describes the reason as a lack of votes rather than any change in the administration's view of her.
The FDA is left without a nominee for its top job. None of the coverage names a replacement or a timeline for choosing one.
What to watch
The obvious open question is who the White House picks next, and whether that person can clear a Senate that just signaled it would not back Overton.
Also worth watching is whether the objections that sank this nomination, described as Republican and, by one outlet, bipartisan, shape the profile of the next candidate.


